ATE354584T1 - Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen - Google Patents

Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen

Info

Publication number
ATE354584T1
ATE354584T1 AT04029270T AT04029270T ATE354584T1 AT E354584 T1 ATE354584 T1 AT E354584T1 AT 04029270 T AT04029270 T AT 04029270T AT 04029270 T AT04029270 T AT 04029270T AT E354584 T1 ATE354584 T1 AT E354584T1
Authority
AT
Austria
Prior art keywords
solid phase
unprotected
aqueous solutions
chemical ligation
native chemical
Prior art date
Application number
AT04029270T
Other languages
English (en)
Inventor
Lynne Canne
Stephen B H Kent
Reyna Simon
Original Assignee
Gryphon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gryphon Therapeutics Inc filed Critical Gryphon Therapeutics Inc
Application granted granted Critical
Publication of ATE354584T1 publication Critical patent/ATE354584T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/08—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents
    • C07K1/086—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents containing sulfur
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C07K1/023—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution using racemisation inhibiting agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C07K1/026—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution by fragment condensation in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
AT04029270T 1997-06-13 1998-06-12 Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen ATE354584T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4955397P 1997-06-13 1997-06-13

Publications (1)

Publication Number Publication Date
ATE354584T1 true ATE354584T1 (de) 2007-03-15

Family

ID=21960431

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04029270T ATE354584T1 (de) 1997-06-13 1998-06-12 Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen
AT98929035T ATE285415T1 (de) 1997-06-13 1998-06-12 Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT98929035T ATE285415T1 (de) 1997-06-13 1998-06-12 Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen

Country Status (9)

Country Link
US (4) US6326468B1 (de)
EP (1) EP1001968B1 (de)
JP (1) JP2002505672A (de)
AT (2) ATE354584T1 (de)
AU (1) AU745094B2 (de)
CA (1) CA2292724A1 (de)
DE (2) DE69828287T2 (de)
ES (2) ES2282788T3 (de)
WO (1) WO1998056807A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184344B1 (en) * 1995-05-04 2001-02-06 The Scripps Research Institute Synthesis of proteins by native chemical ligation
US6849428B1 (en) * 1997-03-05 2005-02-01 New England Biolabs, Inc. Intein-mediated protein ligation of expressed proteins
CA2292724A1 (en) * 1997-06-13 1998-12-17 Gryphon Sciences Solid phase native chemical ligation of unprotected or n-terminal cysteine protected peptides in aqueous solution
CA2301846A1 (en) 1997-09-04 1999-03-11 Gryphon Sciences Modular protein libraries and methods of preparation
AUPP589598A0 (en) 1998-09-14 1998-10-08 University Of Queensland, The Novel peptides
US7001745B1 (en) * 1998-09-30 2006-02-21 New England Biolabs, Inc. Intein mediated peptide ligation
EP1159289A1 (de) * 1999-03-11 2001-12-05 Gryphon Sciences Chemische synthese und verwendung von löslichen membranproteinrezeptordomänen
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
EP1307214A4 (de) * 2000-08-11 2006-01-18 Invitrogen Corp Hochhomogene molekulare marker für ektrophorese
US20040014082A1 (en) * 2000-08-11 2004-01-22 Invitrogen Corporation Highly homogeneous molecular markers for electrophoresis
WO2002018417A1 (en) * 2000-09-01 2002-03-07 Gryphon Therapeutics, Inc. Nucleophile-stable thioester generating compounds, methods of production and use
AU2002243645A1 (en) * 2001-01-22 2002-07-30 Sangamo Biosciences, Inc. Zinc finger proteins for dna binding and gene regulation in plants
EP1748078B1 (de) * 2001-03-09 2011-01-19 Boston Probes, Inc. Kombinationsoligomere betreffende Verfahren, Kits und Zusammensetzungen
GB0113657D0 (en) * 2001-06-05 2001-07-25 Geneprot Inc Improved native chemical ligation with three or more components
ES2411007T3 (es) 2001-10-10 2013-07-04 Novo Nordisk A/S Remodelación y glicoconjugación de péptidos
ES2340376T3 (es) * 2002-06-10 2010-06-02 Amylin Pharmaceuticals, Inc. Desproteccion del azufre posterior a la escision para la sintesis convergente de proteinas mediante ligacion quimica.
CA2448513A1 (en) * 2002-06-29 2003-12-29 Aquanova German Solubilisate Technologies (Agt) Gmbh Isoflavone concentrates, as well as methods for their production
US7166574B2 (en) * 2002-08-20 2007-01-23 Biosurface Engineering Technologies, Inc. Synthetic heparin-binding growth factor analogs
US7598224B2 (en) * 2002-08-20 2009-10-06 Biosurface Engineering Technologies, Inc. Dual chain synthetic heparin-binding growth factor analogs
US8227411B2 (en) 2002-08-20 2012-07-24 BioSurface Engineering Technologies, Incle FGF growth factor analogs
WO2004053460A2 (en) * 2002-12-11 2004-06-24 New England Biolabs, Inc. Carrier-ligand fusions and uses thereof
AU2003303595A1 (en) 2002-12-30 2004-07-29 Gryphon Therapeutics, Inc. Water-soluble thioester and selenoester compounds and methods for making and using the same
PL1615945T3 (pl) 2003-04-09 2012-03-30 Ratiopharm Gmbh Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
ATE497783T1 (de) * 2003-05-06 2011-02-15 Syntonix Pharmaceuticals Inc Gerinnungsfaktor vii-fc chimäre proteine zur behandlung von hämostatischen krankheiten
WO2004105685A2 (en) * 2003-05-22 2004-12-09 Gryphon Therapeutics, Inc. Displaceable linker solid phase chemical ligation
US7414028B1 (en) * 2004-02-04 2008-08-19 Biosurface Engineering Technologies, Inc. Growth factor analogs
US20060024347A1 (en) * 2004-02-10 2006-02-02 Biosurface Engineering Technologies, Inc. Bioactive peptide coatings
US7671012B2 (en) 2004-02-10 2010-03-02 Biosurface Engineering Technologies, Inc. Formulations and methods for delivery of growth factor analogs
US20080227696A1 (en) 2005-02-22 2008-09-18 Biosurface Engineering Technologies, Inc. Single branch heparin-binding growth factor analogs
US7528105B1 (en) 2004-02-10 2009-05-05 Biosurface Engineering Technologies Heterodimeric chain synthetic heparin-binding growth factor analogs
ATE482228T1 (de) 2004-02-20 2010-10-15 Biosurface Eng Tech Inc Positiver modulator des knochenmorphogenetisches protein-2 (bmp-2)
MXPA06011679A (es) 2004-04-09 2007-01-23 Chugai Pharmaceutical Co Ltd Novedosos profarmacos solubles en agua.
WO2005115433A2 (en) * 2004-05-24 2005-12-08 Rigel Pharmaceuticals, Inc. Methods for cyclizing synthetic polymers
NZ578299A (en) 2005-03-31 2010-03-26 Amylin Pharmaceuticals Inc Amylin and amylin agonists for treating schizophrenia
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
WO2007100358A2 (en) * 2005-10-07 2007-09-07 University Of Chicago Convergent synthesis of proteins by kinetically controlled ligation
US20090118271A1 (en) * 2005-10-19 2009-05-07 Chugai Seiyaku Kabushiki Kaisha Preventive or Therapeutic Agents for Pancreatic Cancer, Ovarian Cancer, or Liver Cancer Comprising a Novel Water-Soluble Prodrug
US7820172B1 (en) 2006-06-01 2010-10-26 Biosurface Engineering Technologies, Inc. Laminin-derived multi-domain peptides
WO2007150053A2 (en) 2006-06-22 2007-12-27 Biosurface Engineering Technologies, Inc. Composition and method for delivery of bmp-2 amplifier/co-activator for enhancement of osteogenesis
US8309522B2 (en) 2007-02-05 2012-11-13 Amylin Pharmaceuticals, Llc Neuromedin and FN-38 peptides for treating psychiatric diseases
JP2010537984A (ja) * 2007-08-28 2010-12-09 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ ポリペプチドおよび蛋白質の化学合成のための方法および中間体
CA2790343A1 (en) * 2010-02-18 2011-08-25 Advanced Proteome Therapeutics Inc. Site-specific modification of proteins through chemical modification enabling protein conjugates, protein dimer formation, and stapled peptides
JP6121330B2 (ja) 2010-09-28 2017-04-26 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 作用持続時間が増した改変ポリペプチド
MX351128B (es) 2010-09-28 2017-10-03 Aegerion Pharmaceuticals Inc Polipeptidos manipulados que tienen duracion de accion incrementada.
US20140256621A1 (en) 2011-07-08 2014-09-11 Astrazeneca Pharmaceuticals Lp Engineered poypeptides having enhanced duration of action and reduced immunogenicity
CN104271588B (zh) 2011-07-08 2017-10-10 安米林药品有限责任公司 具有增强的作用持续时间和降低的免疫原性的工程改造的多肽
FR2981352B1 (fr) * 2011-10-17 2015-07-03 Centre Nat Rech Scient Procede de synthese de proteines
JP6290187B2 (ja) 2012-05-11 2018-03-07 クランツ，アレクサンダー 癌の処置のためのタンパク質の部位特異的標識及び標的送達
WO2013177231A1 (en) 2012-05-21 2013-11-28 Massachusetts Institute Of Technology Translocation of non-natural chemical entities through anthrax protective antigen pore
TWI745671B (zh) 2013-03-15 2021-11-11 美商百歐維拉提夫治療公司 因子ｉｘ多肽調配物
US11273176B2 (en) 2016-03-02 2022-03-15 The Brigham And Women's Hospital, Inc. Use of PLA2G5-deficient suppressive macrophages in suppression of inflammation
US11214592B2 (en) * 2017-03-02 2022-01-04 Glytech, Inc. Production method for amino-acid polymer
WO2020070587A1 (en) 2018-10-01 2020-04-09 Université De Genève Methods for producing a plurality of polypeptide variants suitable for biological analysis
US12103947B2 (en) * 2018-11-30 2024-10-01 Glytech, Inc. Methods for producing peptide thioester and peptide
CA3157359A1 (en) 2019-10-10 2021-04-15 1859, Inc. Methods and systems for microfluidic screening
AU2019284038B1 (en) * 2019-10-23 2021-01-07 Mabplex International Co., Ltd. Oligopeptide linker intermediate and preparation method thereof
WO2022266467A2 (en) 2021-06-17 2022-12-22 Dana-Farber Cancer Institute, Inc. Recombinant histone polypeptide and uses thereof
EP4646232A1 (de) 2023-01-06 2025-11-12 Université de Genève Variante ligandkonjugate zur nutzlastabgabe

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5064940A (en) * 1988-05-11 1991-11-12 Protein Technologies, Inc. Premixed dry reagent containing a protected amino acid and an activating agent for use in solid phase protein synthesis
US5101059A (en) * 1989-12-05 1992-03-31 Research Corporation Technologies, Inc. Amino acid protecting groups
CA2218620C (en) 1995-05-04 2007-02-27 Stephen B. H. Kent Synthesis of proteins by native chemical ligation
WO1998028434A1 (en) 1996-12-24 1998-07-02 The Scripps Research Institute General chemical ligation
CA2292724A1 (en) * 1997-06-13 1998-12-17 Gryphon Sciences Solid phase native chemical ligation of unprotected or n-terminal cysteine protected peptides in aqueous solution
US6329468B1 (en) * 2000-01-21 2001-12-11 Bostik Findley, Inc. Hot melt adhesive based on semicrystalline flexible polyolefins

Also Published As

Publication number Publication date
AU8069598A (en) 1998-12-30
CA2292724A1 (en) 1998-12-17
US20020169282A1 (en) 2002-11-14
US20020132975A1 (en) 2002-09-19
AU745094B2 (en) 2002-03-14
US20050209440A1 (en) 2005-09-22
US7094871B2 (en) 2006-08-22
US7030217B2 (en) 2006-04-18
DE69837170T2 (de) 2007-11-22
JP2002505672A (ja) 2002-02-19
DE69828287D1 (de) 2005-01-27
EP1001968B1 (de) 2004-12-22
DE69837170D1 (de) 2007-04-05
ATE285415T1 (de) 2005-01-15
US6326468B1 (en) 2001-12-04
DE69828287T2 (de) 2005-12-15
ES2235336T3 (es) 2005-07-01
EP1001968A1 (de) 2000-05-24
ES2282788T3 (es) 2007-10-16
WO1998056807A1 (en) 1998-12-17

Similar Documents

Publication Publication Date Title
ATE354584T1 (de) Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen
Brancia et al. Improved matrix‐assisted laser desorption/ionization mass spectrometric analysis of tryptic hydrolysates of proteins following guanidination of lysine‐containing peptides
CA2276614A1 (en) Analogs of parathyroid hormone
GB2330450B (en) Chemical ionization source for mass spectrometry
NZ527053A (en) Modified amyloid precursor protein polynucleotides and polypeptides
ATE214419T1 (de) Heisshärtende wäschefeste rohbau-versiegelung
WO2003057845A3 (en) Automated systems and methods for analysis of protein post-translational modification
DK0881906T3 (da) Farmaceutisk sammensætning til immunmodulation, som er baseret på peptider og adjuvanser
GB2308227B8 (en) Electrospray and atmospheric pressure chemical ionization mass spectrometer and ion source
DE69703449D1 (de) Neuroaktive peptide
WO2003074992A3 (en) Phosphorylated proteins and uses related thereto
NO995891L (no) LH-RH peptidanaloger, anvendelser og farmasoeytiske blandinger inneholdende disse
Kidwell et al. Sequencing of peptides by secondary ion mass spectrometry
AU8812498A (en) Chimeric polypeptide comprising the fragment b of shiga toxin and peptides of therapeutic interest
WO2004018644A3 (en) HETEROGENEOUS FOLDAMERS CONTAINING α, β, AND/OR Ϝ-AMINO ACIDS
GB9816514D0 (en) Novel method
AUPR378001A0 (en) Protein chip
WO1999020760A3 (en) Herg family potassium ion channel genes and protein
WO2002037121A3 (en) Detection of modified amino acids by mass spectrometry
AU2002322506A1 (en) Non-affinity based isotope tagged peptides and methods for using the same
WO1999042578A3 (en) Modulation of cell proliferation, methods and reagents
NO982227D0 (no) Urogenitalcarcinom-TPL komplekspeptider og antistoffer derav
ES2158235T3 (es) Peptidos antigenicos con substituciones de glicina.
EP1518862A3 (de) Festphasige native chemische Ligation von ungeschützten oder n-cystein-geschützten Peptiden in wässrigen Lösungen
EP1032586A4 (de) Hypusin enthaltende peptide

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties